[Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy].
Pedersen
T R
TR
Medizinische Abteilung, Aker-Krankenhaus, Universität Oslo, Norwegen.
D000328:Adult; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000401:mortality; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D016896:Treatment Outcome
D000960:Hypolipidemic Agents
Sekundärprävention der KHK mit Lipidsenkern. Ergebnisforschung beseitigt die Kontroverse.